The adjuvant use of calciumfructoborate and borax with etanercept in patients with rheumatoid arthritis: Pilot study. This study was designed to evaluate the effects calciumfructoborate (CFB) and sodium tetraborate (NTB) as supplements in Iraqi patients with active rheumatoid arthritis (RA) maintained on etanercept. A double-blind randomized placebo-controlled clinical trial with 60 days types of boron significantly improve the clinical scores, in association with significant decrease in the serum levels of ESR, hsCRP, IL-1α, IL-6, and TNF-α with remarkable superiority for calciumfructoborate (CFB) over sodium tetraborate (NTB), compared to baseline and placebo-treated group. The use of boron, as adjuvant with etanercept, has potentiated therapeutic outcomes in RA patients, and may
Effects of dietary calciumfructoborate supplementation on joint comfort and flexibility and serum inflammatory markers in dogs with osteoarthritis. Our objective was to evaluate the short-term effects of calciumfructoborate (CFB) on gait, joint range of motion, serum inflammatory markers, and owner perception of pain in client-owned dogs. We used 59 osteoarthritic dogs with impairment
Effects of CalciumFructoborate on Levels of C-Reactive Protein, Total Cholesterol, Low-Density Lipoprotein, Triglycerides, IL-1β, IL-6, and MCP-1: a Double-blind, Placebo-controlled Clinical Study. Calciumfructoborate (CFB) has been reported as supporting healthy inflammatory response. In this study, we assess the effects of CFB on blood parameters and proinflammatory cytokines in healthy
CalciumFructoborate for Bone and Cardiovascular Health Calciumfructoborate (CF), a natural sugar-borate ester found in fresh fruits and vegetables, is a source of soluble boron. CF contains three forms of borate (diester, monoester, and boric acid) and all are biologically active, both at the intracellular (as free boric acid) and extracellular level (as fructose-borate diester and monoester
Short-term efficacy of calciumfructoborate on subjects with knee discomfort: a comparative, double-blind, placebo-controlled clinical study. Calciumfructoborate (CFB) at a dose of 110 mg twice per day was previously reported to improve knee discomfort during the first 14 days of treatment. In this study, 60 participants with self-reported knee discomfort were randomized into two groups
Oral resveratrol and calciumfructoborate supplementation in subjects with stable angina pectoris: effects on lipid profiles, inflammation markers, and quality of life. This study aimed to evaluate the effects of short-term (60-d) oral supplementation with calciumfructoborate, resveratrol, and their combination on the clinical and biological statuses of subjects with stable angina pectoris groups at the 30-d and 60-d visits. This decrease was greater (39.7% at 60 d) for group 3 (calciumfructoborate), followed by group 2 (resveratrol plus calciumfructoborate, 30.3% at 60 d). The N-terminal prohormone of brain natriuretic peptide was significantly lowered by resveratrol (group 1, 59.7% at 60 d) and by calciumfructoborate (group 3, 52.6% at 60 d). However, their combination (group 2
handicap were assigned in a double-blind, placebo-controlled manner to ingest for 30 days either a placebo (PLA, n = 13) or a dietary supplement containing creatine monohydrate, coffea arabica fruit extract, calciumfructoborate and vitamin D (Strong Drive™, SD, n = 14). Subjects ingested two daily doses for the first two weeks and one daily dose for the remaining two weeks. Participants followed
Joint Health Study Natural dietary health supplements that may improve quality of life by relieving joint discomfort have been of increasing interest. Recent studies have demonstrated promising effects of one such supplement - calciumfructoborate (CFB). Preliminary evidence suggests that CFB may reduce joint discomfort, however, few well-powered studies have been conducted to assess the true joints. Recent studies have demonstrated promising effects of calciumfructoborate (CFB), a generally-recognized-as-safe (GRAS) material and a key active ingredient in several commercially popular joint supplements, due to its potential to acutely as well as chronically improve symptoms of joint discomfort, possibly due to its anti-inflammatory properties. Clinical trials have demonstrated converging